Edwards Lifesciences: Improving Patient Safety and Outcomes: EU-HYPROTECT Registry Demonstrates Reduced Time in Hypotension During Surgery Using Acumen HPI Software
Edwards Lifesciences today announced the results of the EU-HYPROTECT registry which indicates that using Acumen HPI software may help reduce the duration and severity of intraoperative hypotension in patients having non-cardiac surgery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005565/en/
(Graph: Business Wire)
EU-HYPROTECT is a European multicenter prospective observational registry which included in its final analysis 702 patients scheduled for elective major non-cardiac surgery in 12 medical centers in 5 countries (France, Germany, Italy, Spain, UK). It is the first multicenter registry involving a predictive monitoring technology, establishing a large, prospectively collected data base on hypotension management in patients having non-cardiac surgery. All patients had intraarterial blood pressure monitoring with an arterial catheter and intraoperative Acumen HPI software.
Both the duration and severity of intraoperative hypotension are associated with postoperative complications. The primary endpoint of this registry, therefore, was intraoperative hypotension quantified using the time-weighted average mean arterial pressure (MAP) <65 mmHg. Secondary endpoints included the proportion of patients with at least one ≥1-min-episode of a MAP <65 mmHg, and the number of ≥1-min-episodes of a MAP <65 mmHg.
Between September 2021 and May 2022, 749 patients were enrolled in the registry and 702 included in the final analysis. The median time-weighted average MAP <65 mmHg was 0.03 (0.00, 0.20) mmHg. 285 patients (41%) had no ≥1-min-episode of a MAP <65 mmHg – 417 patients (59%) had at least one. The median number of ≥1-min-episodes of a MAP <65 mmHg was 1 (0, 3).
In addition, although the study was not powered for this outcome, the incidence of acute kidney injury was at the lower end of what is reported in patients having major non-cardiac surgery.
In Europe, of the 2.5 million patients undergoing high-risk surgery annually, one in four develops serious postoperative complications1,2. Throughout the hospital patient journey, anaesthetists and intensivists need to analyse large amounts of data to make life-critical decisions for patients. One example is critical drops in blood pressure known as hypotension. Intraoperative hypotension is common in patients having non-cardiac surgery under general anaesthesia3. Intraoperative hypotension is associated with increased mortality and major postoperative complications (myocardial injury, acute kidney injury)(4-8).
These postoperative complications come with a significant cost burden for healthcare systems as they are linked with rehospitalisations and increased morbidity.9
“Avoiding intraoperative hypotension is a complex task for anesthetists. Current hypotension treatment is mainly reactive, sometimes only being initiated after the blood pressure has already dropped below safe levels”, explains Prof. Bernd Saugel (Hamburg, Germany).
Edwards Lifesciences has developed the Acumen HPI software, which provides clinicians with information regarding the likelihood that a patient will develop hypotension. Based on an algorithm that calculates data from hemodynamic monitoring in perioperative management, it leverages predictive analytics to alert clinicians of potential blood pressure drops before they occur.
“Predictive hemodynamic monitoring may be a promising approach to help clinicians better manage hypotension. It is intriguing to investigate innovations that can support clinicians in clinical decision making and potentially improve quality of care,” commentsProf. Bernd Saugel (Hamburg, Germany).
“The consequences of the COVID-19 pandemic have drastically accelerated the need for solutions that improve patient safety and outcomes, reduce hospital length of stay and increase hospital efficiencies. The results of the EU-HYPROTECT registry are promising and demonstrate the need to better monitor hypotension in the perioperative pathway. Improving patient safety and outcomes is our ultimate goal and we believe the use of predictive monitoring can help achieve this.” comments Pr Thomas Scheeren, Senior Director Medical Affairs EMEACLA at Edwards Lifesciences.
The full results of the EU-HYPROTECT registry were published in the British Journal of Anaesthesia and can be consulted on https://www.bjaopen.org/article/S2772-6096(23)00019-9/fulltext
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.
Edwards, Edwards Lifesciences, the stylized E logo, Acumen, Acumen HPI, HPI and Hypotension Prediction Index are trademarks of Edwards Lifesciences Corporation and its affiliates. All other trademarks are the property of their respective owners. This statement is made on behalf of Edwards Lifesciences Corporation and its subsidiaries.
###
References:
1Preoperative Score to Predict Postoperative Mortality – POSPOM Edward’s Presentation
2Ghaferi AA et al. Variation in hospital mortality associated with inpatient surgery. N Engl J Med, 2009.
3Bijker JB, van Klei WA, Kappen TH, van Wolfswinkel L, Moons KG, Kalkman CJ: Incidence of intraoperative hypotension as a function of the chosen definition: literature definitions applied to a retrospective cohort using automated data collection. Anesthesiology 2007, 107(2):213-220.
4Gregory A, Stapelfeldt WH, Khanna AK, Smischney NJ, Boero IJ, Chen Q, Stevens M, Shaw AD: Intraoperative Hypotension Is Associated With Adverse Clinical Outcomes After Noncardiac Surgery. Anesth Analg 2020.
5Salmasi V, Maheshwari K, Yang D, Mascha EJ, Singh A, Sessler DI, Kurz A: Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney and Myocardial Injury after Noncardiac Surgery: A Retrospective Cohort Analysis. Anesthesiology 2017, 126(1):47- 65
6Sessler DI, Khanna AK: Perioperative myocardial injury and the contribution of hypotension. Intensive care medicine 2018, 44(6):811-822
7Sun LY, Wijeysundera DN, Tait GA, Beattie WS: Association of Intraoperative Hypotension with Acute Kidney Injury after Elective Noncardiac Surgery. Anesthesiology 2015, 123(3):515-523.
8Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI: Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology 2013, 119(3):507-515
9Vonlanthen R, Slankamenac K, Breitenstein S, Puhan MA, Muller MK, Hahnloser D, Hauri D, Graf R, Clavien PA. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. Ann Surg. 2011 Dec;254(6):907-13. doi: 10.1097/SLA.0b013e31821d4a43. PMID: 21562405.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005565/en/
Contact information
Media Contact:
Julie Tracol
Julie_tracol@edwards.com
+41 (0)75 431 74 95
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP)19.12.2025 18:42:00 CET | Press Release
EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this transaction and embark on the next chapter of our partnership with TgP,” said Matt Hartman, EIG’s Global Head of Infrastructure. “Our priority is to support TgP’s operational excellence and long-term stability, delivering value for customers and stakeholders throughout Peru.” About EIG EIG is a leading institutional investor in the global energy and infrastructure sectors with $24.3 billion assets under management as of September 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.7 billion to the energ
Klarna Partners With Coinbase to Add Stablecoin to Funding Mix19.12.2025 18:00:00 CET | Press Release
Klarna, the global digital bank and flexible payments provider, has partnered with Coinbase to add stablecoin funding to its broad range of traditional sources of funding, which include consumer deposits, long-term loans and short-dated commercial paper. The digital bank plans to raise short-term funding from institutional investors denominated in USDC utilizing Coinbase’s digitally native infrastructure. Adding a USDC-denominated funding source enables Klarna to access USD-like funding directly, tapping into a new pool of institutional investors. “This is an exciting first step into a new way to raise funding,” said Niclas Neglén, Chief Financial Officer, Klarna, “Stablecoin connects us to an entirely new class of institutional investors, and gives us the potential to diversify our funding sources in ways that simply weren't possible a few years ago. This is just the beginning of how digital assets can work alongside our traditional funding sources." Klarna chose Coinbase for this ini
CyberArk Named a Leader in IDC MarketScape: Worldwide Integrated Solutions for Identity Security 202519.12.2025 17:00:00 CET | Press Release
CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it has been recognized as a Leader in the IDC MarketScape: Worldwide Integrated Solutions for Identity Security 2025 Vendor Assessment. CyberArk extends dynamic privilege controls across all identity types with its unified platform, enabling organizations to improve efficiencies and streamline security operations. This IDC MarketScape report notes, “More change has occurred in the identity security marketplace in the past two years than in almost a decade. Vendors are entering a new phase defined by the emergence of intelligence technologies, none of which are specifically defined by any industry standards. Though different by design, the new adjacent IAM offerings are largely focused on improved vulnerability and threat management visibility and automated and predictive attack detection capabilities.” It also notes, “By addressing these evolving identity types within a unified framework, CyberArk enh
New York Liberty and Ant International’s Alipay+ Announce Multiyear Partnership Focused on Empowerment, Sustainability and Youth Development19.12.2025 14:30:00 CET | Press Release
The New York Liberty and Ant International’s Alipay+, a leading cross-border fintech services platform based in Singapore, today announced a multiyear partnership, making Alipay+ an Official Sponsor and Innovation Partner for Sustainability of the New York Liberty. Through this partnership, Alipay+ and the Liberty will jointly support community programs designed to advance community empowerment, environmental sustainability and youth development across New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219678825/en/ Peng Yang, CEO, Ant International and Clara Wu Tsai, Vice Chair, Brooklyn Sports and Entertainment; Governor, New York Liberty “Our partnership with Alipay+ goes beyond the game,” said Keia Clarke, Chief Executive Officer, New York Liberty. “Together, we are investing in the future of New York—its people, its environment, and its youth. Ant International’s commitment to community empowerment, sustai
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 14:00:00 CET | Press Release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom